---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO; Correction"
date: 2026-02-04 21:48:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-12343
original_published: 2025-07-02 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO; Correction

**Published:** February 04, 2026 21:48 UTC
**Source:** Federal Register
**Original Published:** July 02, 2025 00:00 UTC
**Document Number:** 2025-12343

## Summary

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on May 12, 2025. The document, entitled "Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO," announced the determination of the regulatory review period for ELREXFIO (elranatamab-bcmm) for purposes of patent extension. The document was published with only one of two docket numbers. This document corrects that error.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/07/02/2025-12343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elrexfio-correction)
- API: https://www.federalregister.gov/api/v1/documents/2025-12343

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
